Moderna’s Cancer Vaccine Could Change America in 7 Surprising Ways

Moderna and Merck announced that a personalized mRNA vaccine, intismeran, combined with Keytruda, reduced melanoma recurrence in a late-stage trial. The vaccine is tailored to each patient's tumor genetics. Full data will be presented at a medical meeting and shared with regulators. The companies expect 112,000 new U.S. melanoma cases and 8,500 deaths this year, according to their announcement.

Moderna's shares have surged 402% this year, driven by FDA approval of its flu vaccine, mFLUSIVA, and positive phase 3 results for its cancer vaccine, intismeran autogene. The company's mRNA platform shows promise beyond COVID-19, with a deep pipeline in infectious diseases and oncology. Despite financial challenges, investors see long-term potential in its pipeline.

Moderna's stock surged 177% after announcing positive clinical trial results for an experimental cancer vaccine developed with Merck. The vaccine, using mRNA technology, extended recurrence time in melanoma patients. Moderna's stock later fell 24% to $133.32. Analysts see cancer as a significant growth opportunity for Moderna, despite past challenges and political headwinds.

Samyang Biopharm's stock surged to its daily limit after Moderna and Merck & Co. reported positive Phase 3 results for their mRNA cancer vaccine. Samyang also disclosed preclinical data for its mRNA delivery platform, NanoReady, which showed promising results in non-human primates. Other South Korean biotech stocks with mRNA or oncology ties also saw significant gains.

Moderna (MRNA) and Merck (MRK) reported positive Phase 3 trial results for their personalized cancer vaccine, intismeran autogene, showing longer cancer-free periods in melanoma patients. Shares of both companies surged. The vaccine uses mRNA technology and is tailored to individual tumor mutations. Detailed data and overall survival results are pending. Moderna co-founder Noubar Afeyan is an Armenian-American scientist and entrepreneur.

Moderna and Merck developed a personalized cancer vaccine using AI to identify tumor-specific markers. The vaccine, administered with Keytruda, showed early promise in preventing melanoma recurrence. Full trial data will be presented later this year. Moderna's stock more than doubled, and Merck's shares also rose significantly following the announcement.